This site is intended for healthcare professionals in United Arab Emirates

Search

Menu

Close

Sign InLog Out Our MedicinesTherapy AreasExplore ContentExplore ContentDownloadable materials
VideosLet's ConnectLet's ConnectContact usPfizer medical information

Adverse event reporting can be found at the bottom of the page

Menu

Close

MOA MOA MOA EfficacyEfficacyPALOMA-2 Study designPatient Characteristics Primary endpoint Secondary end point PALOMA-3Study design Patient Characteristics Primary endpoint Secondary end point SurvivalFinal analysis Subgroup analysis Prespecified groups Updated Subgroup analysis Safety Safety PALOMA pooled analysis Adverse reactions  & Laboratory abnormalities PALOMA 2 Adverse Events PALOMA 3 Adverse Events IBRANCE consistent  safety profile Pooled analysis of patients aged ≥65 years in the PALOMA trials No evidence of cumulative or delayed toxicity with up to 50 months Patients with visceral diseases GI ,  Liver toxicities, and QTC Dosing Dosing Once daily dosing Dose Modification Real-World EvidenceReal-world EvidenceIBRANCE is the only CDK4/6 inhibitor with >5 years of real-world experience Real-world data provide additional information Favorable progression free rates IRIS Study In the real world, IBRANCE benefits GuidelinesGuidelinesNCCN Guidelines ESMO Guidelines Support & Services Support & Resources Patient support program/tools Events Materials Videos
Ibrance®  US Prescribing Information  Click Here
1% of patients experienced Grade 3 diarrhoea, and 2.2% and 2.9% experienced Grade ≥3 ALT and AST increases, respectively, across the PALOMA trials1*Stomatitis includes the following PTs: Aphthous stomatitis, cheilitis, glossitis, glossodynia, mouth ulceration, mucosal inflammation, oral pain, oropharyngeal discomfort, oropharyngeal pain and stomatitis.
AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; GI = gastrointestinal; PALOMA = Palbociclib: ongoing trials in the management of breast cancer.

Reference: 1. Master Gulf Levant-LPD-(Ibrance)-Capsules - 75 mg, 100 mg & 125 mg based on USPI date of Revision: December 2022 for UAE.No clinically relevant effects on the QTc interval were reported for IBRANCE1
Scroll left to view table
  • In a PALOMA-2 QTc evaluation substudy, no clinically relevant effects on the QTc interval were reported for IBRANCE*2
    • ​​​​​​​IBRANCE + letrozole at the recommended therapeutic dosing regimen did not prolong the QTc interval to a clinically relevant extent

 
Scroll left to view table
  • The current LPD for IBRANCE does not include provisions for ECG monitoring1:
    • Additional monitoring may be necessary based on the individual patient
  • IBRANCE does not have any special warnings or precautions for use with QTc-prolonging drugs in the current LPD1

 
   
*PALOMA-2 (IBRANCE + letrozole vs. placebo + letrozole in ET-sensitive HR+/HER2- mBC) included a QTc evaluation substudy as a definitive QT interval prolongation assessment for palbociclib.2 Time-matched triplicate ECGs were performed at 0, 2, 4, 6 and 8 hours at baseline (Day 0) and on Cycle 1 Day 14.2 Additional ECGs were collected from all patients for safety monitoring.2 The QT interval was corrected for heart rate using QTcF, QTcB and a study-specific correction factor (QTcS). No patient in the IBRANCE + letrozole arm of the substudy had a maximum post-baseline QTcS or QTcF value of ≥480 ms, or a maximum increase from clock time–matched baseline for QTcS or QTcF values of ≥60 ms.2 The upper bounds of the one-sided 95% CI for the mean change from time-matched baseline for QTcS, QTcF and QTcB at all time points and at steady-state Cmax following repeated administration of 125 mg IBRANCE were less than 10 ms.2 There was no evidence of clinically significant effects of IBRANCE + letrozole on QTc, the PR interval or the QRS complex.2

Cmax= maximum concentration; ECG = electrocardiogram; ET = endocrine therapy; HER2- = human epidermal growth factor receptor 2-negative; HR+ = hormone receptor-positive; LPD: local product document; mBC = metastatic breast cancer; PALOMA-2= letrozole for 1st line treatment of postmenopausal women with ER+/HER2- advanced breast cancer; QTc = QT interval corrected for heart rate; QTcB = QT interval Bazett’s correction; QTcF = QT interval Fridericia’s correction; QTcS = QT interval study-specific correction factor.


Reference: 1. Master Gulf Levant-LPD-(Ibrance)-Capsules - 75 mg, 100 mg & 125 mg based on USPI date of: December 2022 for UAE. 2. Durairaj C, et al. Anticancer Drugs. 2018;29(3):271-280.

Prescribing Information: Master GULF LEVANT-LPD- (Ibrance)- Capsules- 75 mg, 100 mg &125 mg based on USPI Revision date: December 2022 – United Arab Emirates

PP-IBR-ARE-0144

Report Adverse Events 

If you'd like to report an adverse event related to a Pfizer Product from Gulf (UAE, Bahrain, Qatar, Oman and Kuwait), please send an email with the adverse event details to: [email protected]

Pfizerpro accountPfizerPro Account

Access Pfizer materials, resources and receive communications from Pfizer about our products with a Pfizerpro account.

Sign inRegisterAccountSign Out

Copyright © 2023 Pfizer Gulf FZ LLC. All rights reserved.

 

i- The product information provided in this site is intended only for Healthcare Professionals of UAE. The products discussed herein may have different product labeling in different countries.

 

ii- The information provided on this website is intended only for healthcare professionals of UAE.
 

PP-UNP-BHR-0180